ArticleJournal of cardiothoracic surgery2026
Effect of a water-soluble alkylene oxide copolymer based bone hemostat in cardiac surgery: a prospective, multicenter, single-arm study.
Article in Journal of cardiothoracic surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis study evaluated the safety and effectiveness of an Alkylene Oxide Copolymer, Ostene, in controlling bone bleeding in open cardiac surgical patients undergoing median sternotomy.
designSingle arm, prospective, post-market study.
settingThis study was conducted at 3 centers in the United States.
participantsNinety adult median sternotomy patients in whom Ostene was intended to be bone hemostat.
interventionsOstene used to treat bone bleeding during surgical procedure. MEASUREMENTS AND MAIN
resultsSurgical parameters included the area of bone bleeding, severity of bleeding, quantity of Ostene used to stop bone bleeding, time for bone bleeding to stop, time to occurrence of a bone rebleed, and the number of Ostene applications. The use and rationale for using an alternate bone hemostat were also recorded in cases where alternate bone hemostats were used. Adverse events that started from the time of the index procedure until 30 days postoperatively were also recorded. MAIN
resultsIntraoperative bone bleeding was successfully controlled with the application of Ostene in 87 of 89 patients (97.8%) who were eligible for effectiveness analyses. Intraoperative rebleeds were observed in 23 of 90 patients (25.6%) 238.1 ± 61.7 min after hemostasis of the original bleed was achieved. Final hemostasis was achieved by reapplying Ostene in 21 patients and alternate bone hemostats in 2 of the 23 patients. None of the patients in the study had postoperative bone bleeding within 24 h of surgery. Few AEs occurred in the study cohort, all unrelated to Ostene.
conclusionsOstene proved to be effective bone hemostat for the control of intraoperative bone bleeding in cardiac surgical patients undergoing median sternotomy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.